News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xeris Pharmaceuticals Announces Dosing Of First Patient In Phase 2 Clinical Trial Of Its Investigational Soluble Glucagon For The Treatment Of Mild-To-Moderate Hypoglycemia


6/6/2014 8:54:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Austin, Texas, June 5, 2014 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), a clinical stage, specialty biopharmaceutical company developing novel, non-aqueous formulations of injectable drugs, announced today the dosing of the first patient in a Phase 2 clinical study of the company's stable, soluble glucagon in patients with type 1 diabetes under a new US Investigational New Drug (IND) application. Xeris' G-Pen Miniā„¢ (glucagon injection), a room-temperature stable glucagon product, is intended to be an effective and convenient treatment for mild-to-moderate hypoglycemia or low blood sugar.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES